Sarama Resources Ltd (ASX: SRR, TSX-V: SWA) delivered a comprehensive corporate update on 21 April 2026 across three fronts: (i) the divestment of its Western Australian gold assets (Cosmo and Mt Venn Projects) to Riedel Resources Ltd (ASX: RIE) for A$4.6 million in cash and shares, retaining a ~32% interest in Riedel that may rise to ~44% on performance milestones; (ii) confirmation of the procedural timetable for its US$242 million ICSID arbitration against the Government of Burkina Faso, with the Merits Hearing scheduled 22–26 February 2027; and (iii) the acquisition of new copper-gold exploration tenure in the NSW Lachlan Fold Belt.

Executive Chairman Andrew Dinning framed the update as "enhancing value across both the arbitration claim and exploration portfolio" while "minimising dilution to any potential future damages award." In effect, Sarama is restructuring itself around the arbitration claim as its core value driver, while retaining exploration optionality through an equity stake in a well-funded Riedel and a low-cost NSW entry.

Key Facts at a Glance

  • Company: Sarama Resources Ltd (ASX: SRR, TSX-V: SWA)
  • Announcement Date: 21 April 2026
  • WA Gold Sale Consideration: A$4.6M in cash and shares (150M RIE shares + 100M performance rights + A$300k of project-cost payments)
  • Post-deal stake in Riedel: ~32% initial, up to ~44% on milestones
  • Completion Target: June 2026 (subject to shareholder approval and conditions precedent)
  • Arbitration Claim: US$242 million (plus interest), via ICSID
  • Merits Hearing: 22–26 February 2027
  • Respondent: Government of Burkina Faso
  • Legal Counsel: Boies Schiller Flexner (UK) LLP
  • New Tenure: Copper-gold tenements in the Lachlan Fold Belt, NSW

Announcement Overview

The update consolidates three discrete corporate streams into a single coherent strategy. Sarama is selling its WA Cosmo and Mt Venn gold projects into a deal that transforms Riedel into a multi-project explorer, while keeping Sarama economically exposed to those WA assets via a cornerstone equity stake. Simultaneously, the Company is progressing its ICSID arbitration against Burkina Faso to a confirmed Merits Hearing in February 2027. Finally, it is using a low-cost pathway to secure copper-gold exploration tenure in NSW's Lachlan Fold Belt — one of Australia's most prospective copper-gold regions.

Company Background: Sarama Resources Ltd

Sarama Resources Ltd is a dual-listed (ASX: SRR; TSX-V: SWA) exploration company headquartered in Vancouver, Canada. The Company was previously a gold developer in Burkina Faso before the unlawful expropriation of its Tankoro 2 Exploration Permit, which is the central factual basis of its US$242M ICSID arbitration claim. Sarama is led by Executive Chairman Andrew Dinning.

Detailed Analysis

Western Australian Gold Asset Sale to Riedel

Under a binding Share Sale Agreement, Sarama is transferring 100% of its Yikarri Resources Pty Ltd subsidiary — holder of the Cosmo and Mt Venn Projects — to Riedel in exchange for: 150 million Riedel shares; 100 million performance rights in Riedel vesting across four milestone tranches (exploration, mineral resource and share-price targets); and payment of project-related costs capped at A$300,000. Riedel is concurrently raising A$2.5 million at A$0.025 per share to fund exploration, leaving it with a pro-forma cash balance of ~A$4 million.

Andrew Dinning is being appointed a Non-Executive Director of Riedel; Paul Schmiede is proposed as incoming CEO of Riedel; and Jack Hamilton will become Special Advisor — Exploration. Sarama will continue to hold a controlling influence on exploration direction while retaining flexibility to focus management attention on the arbitration claim.

ICSID Arbitration — Procedural Timetable and Merits Hearing

The arbitration arises from the unlawful expropriation of the Tankoro 2 Exploration Permit in Burkina Faso, which was the central component of a multi-million-ounce gold development project. Sarama is seeking US$242 million plus interest before the International Centre for Settlement of Investment Disputes (ICSID). The Company filed its written Memorial on 31 October 2025; the Government of Burkina Faso filed its Counter-Memorial on 30 March 2026. The Procedural Timetable is now agreed, and the Tribunal has confirmed its availability for a Merits Hearing from 22 to 26 February 2027. Document production, further written submissions and pre-hearing steps will follow.

Sarama is represented by Boies Schiller Flexner (UK) LLP, a leading international law firm with extensive investor-state arbitration experience and a strong track record in the natural resources sector.

New NSW Copper-Gold Tenure

Sarama has secured copper-gold exploration tenements in NSW's Lachlan Fold Belt — a district that hosts world-class copper-gold systems including Cadia. The entry is described as "low-cost", preserving balance sheet flexibility while building optionality in copper-gold alongside the Riedel-held gold exposure.

Strategic Significance

Sarama's strategy is coherent: isolate the arbitration claim as the primary value driver, preserve exploration exposure without the cash burn of operating two WA gold projects directly, and build a small-footprint NSW copper-gold presence for optionality. The equity-for-assets structure with Riedel minimises dilution to Sarama shareholders while creating a cornerstone position in a better-capitalised vehicle. The US$242M claim, in a market cap context, is a material embedded optionality.

Market and Investor Impact

For SRR holders, the key question is how the market prices the arbitration claim relative to the Company's enterprise value. The claim is now on a defined procedural path with a fixed hearing window. Post-transaction, Sarama's balance sheet is simplified, its gold exploration exposure is consolidated in Riedel, and its operational attention can be focused on prosecuting the arbitration.

What This Means for Investors

The investment case for Sarama has pivoted substantially. Prior valuations leaned on a blended WA exploration + arbitration narrative; the post-deal Sarama is more explicitly an arbitration-claim vehicle with exploration optionality. Investors should align expectations to the February 2027 Merits Hearing timeline — still roughly 10 months away from the announcement date — and appreciate that awards, if any, can be lengthy to realise.

Risks and Opportunities

Risks

  • Arbitration outcome risk: award quantum, timing and enforceability are all uncertain.
  • RIE share price risk: Sarama's consideration is share-based and exposed to RIE performance.
  • Completion risk: Riedel shareholder approval and conditions precedent are not yet satisfied.
  • Exploration risk: NSW copper-gold ground is early-stage.

Opportunities

  • US$242M claim provides substantial embedded optionality.
  • Merits Hearing scheduled removes prior procedural uncertainty.
  • Cornerstone stake in a reinvigorated multi-project gold explorer (Riedel).
  • Low-cost entry into the Lachlan Fold Belt diversifies commodity exposure.

Key Takeaways

  • SRR sells WA gold assets to RIE for A$4.6M, retains ~32% (up to 44%) in Riedel.
  • ICSID arbitration hearing set for 22–26 February 2027.
  • Claim amount: US$242M plus interest.
  • New NSW copper-gold tenure secured as low-cost optionality.
  • Strategy preserves exploration upside while minimising shareholder dilution against a potential damages award.

Bottom Line

Sarama has reshaped itself into a focused arbitration-plus-optionality vehicle. The Riedel deal monetises WA gold assets without giving them up entirely, the ICSID timetable is now visible, and a small NSW foothold adds copper-gold colour. Value realisation hinges on the February 2027 hearing and the market's willingness to price embedded claim value.

Disclaimer

This article is based solely on the corresponding ASX announcement and is for informational purposes only. It does not constitute financial, investment, legal, or tax advice. Investors should conduct their own due diligence and consult a licensed financial adviser before making investment decisions. Past performance is not indicative of future results.